As Needed Rasburicase

Phase 2Protein / enzyme

MM.D. Anderson Cancer Center

As Needed Rasburicase is one of 5 small molecule programs targeting Tumor Lysis Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tumor Lysis SyndromeActive, not recruiting

Tumor Lysis SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Tumor Lysis Syndrome

#DrugCompanyPhaseTrials

Zyloprim

Alnylam Pharmaceuticals

Phase 3

3 2

Uloric

Takeda

Phase 3

2 3

KRYSTEXXA

HHorizon Therapeutics Ireland DAC

Approved

1 4

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

6 5

As Needed Rasburicase

MM.D. Anderson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tumor Lysis Syndrome1 trial

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00628628·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for As Needed Rasburicase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — As Needed Rasburicase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for As Needed Rasburicase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

As Needed Rasburicase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tumor Lysis Syndrome1 trial

References

Drug Info

Quick Facts

Related News